Sanford Burnham
  • Sanford Burnham
  • Twitter
  • Facebook
  • Youtube
  • Navigate Sanford-Burnham
    • Main Site
    • Our Mission
    • Research
    • Talent
    • Technology
    • Training & Education
    • Our Supporters
    • News

Beaker

Sanford-Burnham Science Blog

Subscribe

The Life and Times of Bcl-2, Part 2

by Josh Baxt on May 10, 2010 at 3:26 pm | 1 comment

One way to beat Bcl-2 is to attack the protein rather than the gene. Dr. Maurizio Pellecchia’s laboratory has been working with Gossypol, a natural product extracted from cotton seeds, which he discovered binds to and neutralizes the Bcl-2 protein. The team chemically modified Gossypol to improve its ability to target Bcl-2, increasing its anti-cancer properties and reducing its toxicity.

Dr. Pellecchia’s research strongly suggests that this new compound, Apogossypol, has great potential as a cancer treatment. In addition to spurring cancer cells to commit suicide, the compound also makes them less resistant to chemotherapy. Dr. Pellecchia thinks Apogossypol may be used to maximize the efficacy of various chemotherapies.

“Chemotherapy only kills the weak cancer cells – those with little defense against apoptosis. With each successive cycle of chemotherapy, the cells with strong anti-apoptotic defenses survive and emerge as chemo-resistant disease that ultimately kills the patient,” says Dr. Pellecchia. “Keeping the levels of Bcl-2 in check during and between chemotherapy cycles should increase the effectiveness of chemo and could prevent the cells that over-express Bcl-2 from proliferating faster.”

Other organizations have recognized Apogossypol’s potential. The National Cancer Institute has provided special support to advance the drug toward clinical trials with an award to Drs. Pellecchia and Reed through its Rapid Access to Innovative Drugs program. Also, Coronado Biosciences, Inc., has taken the Apogossypol project under its wing and is financing the manufacturing and pre-clinical toxicology studies necessary to gain FDA approval for testing in humans.

In still another advance against Bcl-2 by Burnham scientists, Drs. Xiao-kun Zhang and Arnold Satterthwait created a molecule that binds to Bcl-2 and converts it from a tumor protector to a cancer cell killer.

“Our results provide insight into Bcl-2 conversion and identify a new direction for Bcl-2- based drugs and cancer drug development,” says Dr. Zhang. The possibility of turning this cancer friend into a cancer foe is especially appealing, as it would turn the tables on cancer, using the cancer’s self-protective shield as a weapon to help defeat it.

“It’s almost like prying a shield from an attacker and clobbering them on the head with it,” says Dr. Satterthwait. “What was once the key to the cancer’s survival now becomes the means of its destruction.”

Tags: Arnold Satterthwait, Bcl-2, Infectious Diseases, John Reed, La Jolla, Maurizio Pellecchia, Signal Transduction, Xiao-kun Zhang

Post a Comment Cancel reply

* All fields are required

CAPTCHA Image
Refresh Image

*

Search

Find more information

  • About Beaker
  • Contact us
  • Donate

Please take a quick survey

Which of these items describes you?

Select all that apply. (Question 1 of 5)

Categories

  • Basic Research
  • Cancer
    • Apoptosis & Cell Death Research
    • Signal Transduction
    • Tumor Development
    • Tumor Microenvironment
  • Children's Health
    • Genetic Diseases
    • Muscle Development & Regeneration
    • RNA Biology
  • Diabetes & Obesity
    • Cardiovascular Pathobiology
    • Metabolic Signaling & Disease
  • Drug Discovery
  • Events
  • Graduate School of Biomedical Sciences
  • Grants
  • Infectious & Inflammatory Diseases
    • Bioinformatics & Systems Biology
    • Infectious Diseases
    • Inflammatory Diseases
  • Nanomedicine
  • Neuroscience, Aging, & Stem Cells
    • Degenerative Diseases
    • Development & Aging
    • Stem Cells
  • Other
  • People
  • Sanford-Burnham Supporters
  • Translational Medicine

Search by Keyword

CCRA CIRM collaboration commitment communication community Daniel Kelly Erkki Ruoslahti Evan Snyder events Florida Hospital Fred Levine Genetic Disease Program Guy Salvesen Hudson Freeze John Reed Kristiina Vuori La Jolla Lake Nona Metabolic Signaling metabolism NIH Orlando personalized medicine Prebys Center press proteins Rare Diseases Rare disease symposium research publications Robert Wechsler-Reya Santa Barbara Sara Courtneidge Sheila Collins Stem Cells Steven Smith Stuart Lipton T. Denny Sanford technology Translational Research Institute tumor microenvironment Tumor Microenvironment Program Video Yu Yamaguchi Ze'ev Ronai

© Sanford-Burnham Medical Research Institute. All rights reserved.

Get Cloud PHP Hosting on CatN